Havrdova Eva, Kobelt Gisela, Berg Jenny, Capsa Daniela, Gannedahl Mia, Doležal Tomáš
Department of Neurology, Charles University, Praha, Czech Republic.
European Health Economics, Mulhouse, France.
Mult Scler. 2017 Aug;23(2_suppl):41-52. doi: 10.1177/1352458517708117.
In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated.
This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, in the societal perspective, in CZK 2015.
A total of 747 patients (mean age 47 years) participated; 86% were below retirement age and of these, 49% were employed. Employment was related to disease severity, and MS affected productivity at work for 82% of those working. Overall, 92% and 66% of patients experienced fatigue and cognitive difficulties as a problem. Mean utility and annual costs were 0.832 and 257,000CZK at Expanded Disability Status Scale (EDSS) 0-3, 0.530 and 425,500CZK at EDSS 4-6.5 and 0.141 and 489,000CZK at EDSS 7-9. The average cost of a relapse was estimated at 12,600CZK.
This study provides current data on MS in the Czech Republic that are important for the development of health policies.
为了评估针对多发性硬化症（MS）干预措施的价值——其中终身成本和结果无法观察到——结果数据必须与成本相结合。这就要求定期更新成本数据。
本研究是一项在16个国家开展的横断面回顾性研究的一部分，收集了MS患者的资源消耗、工作能力、健康相关生活质量（HRQoL）和常见症状的数据。从社会角度，以2015年捷克克朗为单位，按严重程度进行描述性分析。
共有747名患者（平均年龄47岁）参与；86%未达到退休年龄，其中49%有工作。就业与疾病严重程度相关，MS影响了82%在职患者的工作生产力。总体而言，92%和66%的患者将疲劳和认知困难视为问题。在扩展残疾状态量表（EDSS）0 - 3级时，平均效用和年度成本分别为0.832和257,000捷克克朗；在EDSS 4 - 6.5级时，为0.530和425,500捷克克朗；在EDSS 7 - 9级时，为0.141和489,000捷克克朗。一次复发的平均成本估计为12,600捷克克朗。
本研究提供了捷克共和国MS的当前数据，这些数据对卫生政策的制定很重要。
